Refisolone

Refisolone

CAS202718-04-5

MFC18H24O3 MW288.4 g/mol

(1S,2S,4R,6S,7S,10S,11S)-11-hydroxy-7-methyl-5-oxapentacyclo[8.8.0.02,7.04,6.011,16]octadec-15-en-14-one

10-hydroxy-16α,17α-epoxyestr-4-en-3-one
GABAA receptor antagonist, migraine. PH 80, 2QA794326X

Refisolone (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names PH-80, Salubrin, and ORG-39479), also known as 10-hydroxy-16α,17α-epoxyestr-4-en-3-one, is a vomeropherine (pherine) which is under development for the treatment of hot flashes, migraine, and premenstrual dysphoric disorder (PMDD).[1][2][4][3] It is taken intranasally as a nasal spray.[1][2][3] The pharmacology of refisolone has been studied and reported.[5][6] The drug is under development by Pherin Pharmaceuticals and VistaGen Therapeutics, with the former having been acquired by the latter in 2023.[1][2][4][3] As of December 2025, refisolone is in phase 2 clinical trials for all indications.[1][4] However, a phase 3 trial of refisolone for PMDD is also reported to have been registered in 2015, though its status is listed as unknown.[3][7]

Refisolone (developmental code name PH-80) is an investigational, non-hormonal pherine (vomeropherine) nasal spray currently in Phase 2 clinical trials for the treatment of menopausal hot flashes (vasomotor symptoms), migraines, and premenstrual dysphoric disorder (PMDD).

Mechanism of Action

Unlike conventional menopausal treatments, Refisolone does not rely on systemic hormone replacement. It is administered intranasally at microgram-level doses to achieve a rapid, on-demand effect. The spray works by activating chemosensory neurons in the nasal cavity, which send signals to the olfactory-limbic and olfactory-hypothalamic pathways in the brain to regulate anxiety and correct body temperature neural circuits.

Current Clinical Status

  • FDA Status: The US FDA cleared the Investigational New Drug (IND) application for Refisolone, issuing a “Study May Proceed” letter to allow advanced Phase 2 trials to move forward.
  • Development History: The compound was originally created by Pherin Pharmaceuticals, which was fully acquired by Vistagen Therapeutics.
  • Clinical Trial Progress: A successful Phase 2a exploratory trial for menopausal hot flashes was completed in Mexico, showing that the compound was well-tolerated with no serious drug-related adverse events.

Intranasal PH80 Spray for Acute Management of the Symptoms of Premenstrual Dysphoric DisorderCTID:

NCT01217775, Phase:Phase 3Status:Unknown status, Date:2015-12-03

PAT

WO2009126825

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2009126825&_cid=P21-MT2BVX-74335-1

The preparation of the estrene compound 16α,17α-epoxy-10β-hydroxyestr-4-en-3-one is described in commonly assigned US Pat. No. 6,057,439, which is incorporated herein by reference. The steroid compound 16α,17α-epoxy-10β-hydroxyestr-4-en-3-one has the chemical structure of:

PAT

WO2025217068

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2025217068&_cid=P21-MT2BVX-74335-2

16a, 17a epoxyestr-4 en-iop ol-3 one will not be associated with or cause endometrial effects such as endometrial hyperplasia or endometrial cancer as are associated with conventional estrogen therapies.

[0054] US Patent No. 6,057,439 (“US 6,057,439) describes the use of a number of steroidal pherines for the treatment of premenstrual dysphoric disorder and anxiety by administration to the vomeronasal organ of an individual suffering from those symptoms. Among the pherines described in U.S. Pat. 6,057,439 is 16a,17a-Epoxyestr-4-en-10|3-ol-3-one, which is also known in the art as PH80, has the following chemical structure:

.S. Pat. 6,057,439 also describes the synthesis of 16a,17a-Epoxyestr-4-en-10p-ol-3-one and pharmaceutical compositions containing it for alleviating symptoms of PMDD. U.S. Pat. 6,331,534 describes the same steroids for alleviating pain by vomeronasal administration. U.S. Pat. 8,431,559, “Treatment of hot flashes”, describes a synthesis of 16a,17a-epoxyestr-4-en-10p-ol-3-one, which it refers to as 16a,17a-epoxy-10p-hydroxyestr-4-en-3-one, and a method of using 16a,17a-epoxyestr-4-en-10p-ol-3-one to alleviating hot flashes by administering 16a,17a-epoxyestr-4-en-10p-ol-3-one via intranasal administration. U.S.

Pat. 11,419,881, “Treatment of migraine”, similarly describes a synthesis of 16a,17a-epoxyestr-4-en-10P-ol-3-one and also refers to the drug as 16a,17a-epoxy-10p-hydroxyestr-4-en-3-one. U.S. Pat. 11,419,881 also describes a method for alleviating migraines by nasally administering 16a,17a-epoxyestr-4-en-10p-ol-3-one .

PAT

ADVERISEMENT

ANAX LABORATORIES

WEBSITE https://www.anaxlab.com/

Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences

Development Solutions, Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales

SEE MORE………Integrated Solutions, Manufacturing Solutions, Products,
Can’t Find? Let’s Connect

Phone : +91 897704 2010 /  +91 9177075735, Email : info@anaxlab.com

#MedicinalChemistry, #DrugDiscovery, #OrganicSynthesis, #ChemicalLibrary, #BuildingBlocks, #SARStudies, #ChemistryInnovation, #medchem, #Drugdevelopment, #Biotech, #Biotechnology, #AnaxLaboratories, #Pharma

str1

AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

wdt-16

join me on Linkedin

Anthony Melvin Crasto Ph.D – India | LinkedIn

join me on Researchgate

RESEARCHGATE

This image has an empty alt attribute; its file name is research.jpg

join me on Facebook

Anthony Melvin Crasto Dr. | Facebook

join me on twitter

Anthony Melvin Crasto Dr. | twitter

+919321316780 call whatsaapp

EMAIL. amcrasto@gmail.com

References

References

  1.  “VistaGen Therapeutics”. AdisInsight. Springer Nature Switzerland AG. 2 December 2025. Retrieved 9 March 2026.
  2.  “Pherin Pharmaceuticals”. AdisInsight. Springer Nature Switzerland AG. 28 July 2024. Retrieved 9 March 2026.
  3.  “PH-80 Drug Profile”. Ozmosi. Retrieved 9 March 2026.
  4.  “Delving into the Latest Updates on Refisolone”. Synapse. PatSnap. 28 February 2026. Retrieved 9 March 2026.
  5.  Monti L, Baker RA, Hanover R (25 November 2025). Refisolone PH80 Nasal Spray Effects on In Vitro Receptor Binding, Reproductive Organs in Mice, and Pharmacokinetic Profile in Humans. The Menopause Society 2025 Annual Meeting.
  6.  Monti L, Baker RA, Hanover R (25 November 2025). Refisolone PH80 Nasal Spray Effects on Brain and Autonomic Activity: A Novel, Investigational, Rapid-Onset Non-Hormonal Treatment for Vasomotor Symptoms Due to Menopause. The Menopause Society 2025 Annual Meeting.
  7.  Clinical trial number NCT01217775 for “Intranasal PH80 Spray for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder (PH80-PMD)” at ClinicalTrials.gov

External links

Clinical data
Other namesPH-80; PH80; PH-80-M; PH80-M; PH80M; PH80-PMD NS; PH80-HF; PH80-HF NS; Salubrin; Salubrin HF; ORG-39479; ORG39479; 10-Hydroxy-16α,17α-epoxyestr-4-en-3-one; 16α,17α-Epoxyestr-4-en-10-ol-3-one
Routes of
administration		Intranasal (nasal spray)[1][2][3]
Drug classVomeropherine
Identifiers
IUPAC name
CAS Number202718-04-5
PubChem CID21968346
UNII2QA794326X
Chemical and physical data
FormulaC18H24O3
Molar mass288.387 g·mol−1
3D model (JSmol)Interactive image
SMILES
InChI

//////////refisolone, anax labs, GABAA receptor antagonist, migraine. PH 80, 2QA794326X

Leave a Reply

Your email address will not be published. Required fields are marked *

➤